Stay updated with breaking news from Mark Garzotto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings from the phase 3 randomized CABASTY clinical trial “may be practice changing,” investigators reported. Biweekly vs triweekly cabazitaxel for mCRPC in men aged 65 years or older has similar efficacy but is associated with a lower risk for neutropenia and/or neutropenic complications.
Radical cystectomy with extended vs standard lymph node dissection (LND) offers no advantage for tumor recurrence or overall survival.
email article Perioperative treatment to preserve nerve function did not significantly improve erectile function after surgery for prostate cancer, a randomized, placebo-controlled study showed. Six months after radical prostatectomy, patients treated with erythropoietin (EPO) or placebo had similar scores on a validated scale of erectile function. In fact, the median score favored the placebo group (19 vs 14). Investigators also found no significant difference between groups at 3, 9, and 12 months. Adjustment for nerve-sparing surgery, which was associated with recovery of erectile fun...
PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough Published 05 January 2021 Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been strongly linked with prostate cancer progression and metastatic potential. 1 Loss of the inhibitory phosphatase, PTEN, leading to hyperactivation of PI3K/AKT/mTOR oncogenic signaling, occurs in 40-50% of metastatic castration-resistant prostate cancer. 1,2 Not surprising is the fact that PTEN loss in patients with metastatic castration-resistant prostate cancer is associat...